Santhera Pharmaceuticals Appoints Catherine Isted as CFO

Santhera Pharmaceuticals (SIX: SANN) has announced the appointment of Catherine Isted as Chief Financial Officer (CFO), effective February 24, 2025. She succeeds Andrew Smith, who steps down after five years of shaping the company’s financial stability. Smith, instrumental in securing funding and establishing a strong commercial foundation, will assist in the transition over the coming months. Isted brings over 25 years of experience in life sciences finance, corporate development, and investment banking, with previous leadership roles at BenevolentAI, ReNeuron Group, and Oxford Biomedica.

With a background spanning healthcare investment banking and financial operations, Isted is set to guide Santhera’s commercial expansion. Her expertise in investor relations and corporate strategy aligns with the company’s vision as it advances its growth trajectory. Santhera’s strong financial position, secured under Smith’s leadership, supports operations through mid-2026, allowing Isted to focus on driving further strategic progress. Her appointment marks a pivotal moment as Santhera continues to strengthen its presence in the biopharmaceutical sector.